The persistence of p190 BCR-ABL transcripts is associated with lower probability of molecular response to imatinib in early and late chronic phase CML patients.

被引：0
|
作者：
Garuti, A
Ibatici, A
Cirmena, G
Miglino, M
Varaldo, R
Nicoletta, C
Grasso, R
Pozzi, S
Podesta, M
Gobbi, M
Sessarego, M
Patrone, F
Frassoni, F
机构：
[1] Osped San Martino Genova, Dept HematoOncol, Ctr Cellule Staminali & Terapia Cellulare, Genoa, Italy
[2] Osped San Martino Genova, Dipartimento Med Interna, Genoa, Italy
[3] Osped San Martino Genova, Clin Ematol, Genoa, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.3282.3282
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3282
引用
收藏
页码：917A / 918A
页数：2
相关论文
共 50 条
  • [41] RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES
    Saglio, S.
    Hughes, T.
    Kim, D. W.
    Hanfstein, B.
    Gottardi, E.
    Branford, S.
    Goh, H.
    Beppu, L.
    Soverini, S.
    Shou, Y.
    Stein, A.
    Woodman, R.
    Kantarjian, H.
    Radich, J.
    Hochhaus, A.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 342 - 343
  • [42] Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
    Moravcová, J
    Zmeková, V
    Klamová, H
    Voglová, J
    Faber, E
    Michalová, K
    Rabasová, J
    Jarosová, M
    LEUKEMIA RESEARCH, 2004, 28 (04) : 415 - 419
  • [43] Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure
    Mueller, M. C.
    Branford, S.
    Radich, J.
    Kim, D. W.
    Martinelli, G.
    Saglio, G.
    Hughes, T.
    Shou, Y.
    Weitzman, A.
    Baccarani, M.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment
    Galimberti, S
    Cervetti, G
    Guerrini, F
    Testi, R
    Pacini, S
    Fazzi, R
    Simi, P
    Petrini, M
    CANCER GENETICS AND CYTOGENETICS, 2005, 162 (01) : 57 - 62
  • [45] BCR-ABL kinase domain mutations in the P-loop and at imatinib contact sites in CML patients with imatinib resistance are associated with higher maximum imatinib doses
    Pelz-Ackermann, Oliver
    Deininger, Michael W. N.
    Cross, Michael
    Wildenberger, Kathrin
    Krahl, Rainer
    Wang, Song-Yau
    Ai-Ali, Haifa K.
    Niederwieser, Dietger W.
    Lange, Thoralf
    BLOOD, 2007, 110 (11) : 858A - 858A
  • [46] Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
    Lin, Han-Xin
    Sjaarda, Jenny
    Dyck, Jocob
    Stringer, Randa
    Hillis, Chris
    Harvey, Maria
    Carter, Ronald
    Ainsworth, Peter
    Leber, Brian
    Pare, Guillaume
    Sadikovic, Bekim
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (04) : 360 - 366
  • [47] Molecular response according to type of preexisting BCR-ABL mutations after second line dasatinib therapy in chronic phase CML patients
    Mueller, C.
    Erben, Philipp
    Ernst, Thomas
    Giehl, Michelle
    Schenk, Thomas
    Koffmann, Jana
    Lauber, Stephanie
    Kruth, Jens
    Hanfstein, Benjamin
    Bleickardt, Eric
    Nicaise, Claude
    Hehlmann, Rudiger
    Hochhaus, Andreas
    BLOOD, 2007, 110 (11) : 100A - 101A
  • [48] For CML patients in chronic phase who achieve a cytogenetic response to imatinib the finding of a BCR-ABL mutation predicts for progression to advanced phase but it has no such significance in primary resistance
    Lavallade, Hugues
    Khorashad, Jamshid S.
    Milojkovic, Dragana
    Wagner, Simon
    Kaeda, Jaspal
    Goldman, John M.
    Apperley, Jane F.
    Marin, David
    BLOOD, 2007, 110 (11) : 102A - 102A
  • [49] RESPONSE TO NILOTINIB IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) ACCORDING TO BCR-ABL MUTATIONS AT BASELINE
    Radich, J.
    Kim, D. -W
    Martinelli, G.
    Soverini, S.
    Branford, S.
    Mueller, M.
    Haque, A.
    Shou, Y.
    Hochhaus, A.
    Hughes, T.
    Saglio, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 55 - 55
  • [50] A prospective analysis of the consequences of imatinib mesylate inhibition of sensitive kinases other than BCR-ABL in patients with previously untreated early chronic phase CML.
    Seymour, JF
    Grigg, AP
    Matthews, J
    Taylor, K
    Guzzo-Pernell, N
    Mills, AK
    Lynch, K
    Hughes, TP
    BLOOD, 2003, 102 (11) : 911A - 911A
12345